ProMIS Neurosciences, Inc.

PMN · Nasdaq · Canada

Share price · PMN

$3.13-11.85 (-79.11%) 3M

close as of 2026-11-18 · 24h delayed · vol 88K (0.3x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when PMN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 30 Oct 2026-70.1%

    Nothing announced by PMN that day or the session before.

  2. 28 Oct 2026+14.4%
  3. 27 Oct 2026+20.1%
  4. 21 Oct 2026+12.9%

    Nothing announced by PMN that day or the session before.

  5. 9 Sep 2026+14.6%

    Nothing announced by PMN that day or the session before.

  6. 28 Jul 2026+23.9%
  7. 23 Jul 2026-9.9%

    Nothing announced by PMN that day or the session before.

  8. 17 Jul 2026+14.2%
  9. 30 Jun 2026+22.4%
  10. 9 Apr 2026+16.8%

    Nothing announced by PMN that day or the session before.

Share of unusual movement by asset

For each asset, the share of PMN's own-move activity since 30 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
PMN310
events and moves
4shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—0%
Sessions with no dated event—100%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1
Amyloid-beta (monoclonal antibody)Monoclonal antibody
Alzheimer's Disease
Early Alzheimer's Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$6.7M$44M+ <$0.1M short-term inv.$8.2M-$9.4M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$9.5M$53M+ <$0.1M short-term inv.$12M-$10M operating cash flowreport ↗
2026-Q1—$7.0M$64M+ <$0.1M short-term inv.$8.2M-$12M operating cash flowreport ↗
2025-Q3—$9.8M$15M+ <$0.1M short-term inv.$12M-$10M operating cash flowreport ↗
2025-Q2—$8.8M$4.5M+ <$0.1M short-term inv.$10M-$3.9M operating cash flowreport ↗
2025-Q1—$5.5M$8.4M+ <$0.1M short-term inv.$7.3M-$4.9M operating cash flowreport ↗
2024-Q3—$2.6M$22M+ <$0.1M short-term inv.—-$6.7M operating cash flowreport ↗
2024-Q2—$1.6M$1.0M+ <$0.1M short-term inv.$2.6M-$1.5M operating cash flowreport ↗
2024-Q1—$2.1M$2.5M+ <$0.1M short-term inv.$3.6M-$10M operating cash flowreport ↗
2023-Q3—$1.1M$17M+ <$0.1M short-term inv.$2.4M-$2.4M operating cash flowreport ↗
2023-Q2—$1.0M$1.2M+ <$0.1M short-term inv.$2.3M-$2.1M operating cash flowreport ↗
2023-Q1—$3.5M$3.3M+ <$0.1M short-term inv.$5.0M-$2.6M operating cash flowreport ↗
2022-Q3—$4.6M$3.9M+ <$0.1M short-term inv.$6.0M-$4.6M operating cash flowreport ↗
2022-Q2—$3.2M$8.9M+ <$0.1M short-term inv.$2.8M-$4.5M operating cash flowreport ↗
2022-Q1—$1.9M$14M$2.1M-$3.4M operating cash flowreport ↗
2021-Q3—$0.8M$21M$1.2M-$3.0M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$33M$6.1M+ <$0.1M short-term inv.$9.9M-$28M operating cash flowreport ↗

For 2025, ProMIS Neurosciences reported no revenue disclosure for the year or prior year, R&D expenses of $33.38M, up 213.7% YoY from $10.64M, cash and equivalents of $6.12M, and a net loss of $39.72M. No analyst consensus EPS comparison was provided.

The company guided that existing cash, following a February 2026 private placement with gross up-front proceeds of $75.5M as part of a financing of up to $175M, is expected to fund operations through 2027. PRECISE-AD Phase 1b was fully enrolled with 144 patients; six-month assessments are expected in Q2 2026, with a blinded interim analysis anticipated early Q3 2026 and top-line data in early 2027. PMN310 has maintained a favorable safety profile with no treatment-related serious adverse events reported, received FDA Fast Track designation in July 2025, and the company is advancing a subcutaneous formulation, with PMN267 and PMN442 in preclinical development for ALS and synucleinopathies.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$11M$13M+ <$0.1M short-term inv.—-$27M operating cash flowreport ↗
2023-FY—$7.9M$13M+ <$0.1M short-term inv.$3.3M-$11M operating cash flowreport ↗
2022-FY—$16M$5.9M+ <$0.1M short-term inv.$4.5M-$17M operating cash flowreport ↗
2021-FY—$4.6M$17M+ <$0.1M short-term inv.$2.5M-$9.3M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 11 purchases ($8.9M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-04Williams Eugene · directorOpen-market purchase26,500$3.43$91KForm 4
2026-11-02Cashman Neil · director, Chief Scientific OfficerOpen-market purchase10,000$3.86$39KForm 4
2026-10-30Williams Eugene · directorOpen-market purchase1,316$3.99$5KForm 4
2026-10-05Rubino Ivana · Chief Commercial OfficerAward / grant (derivative)80,000——Form 4
2026-08-05Kaplan Johanne · Chief Development OfficerOpen-market purchase2,280$13.30$30KForm 4
2026-05-20Alex Slanix Paul · directorAward / grant (derivative)5,500——Form 4
2026-05-20Kaplan Johanne · Chief Development OfficerAward / grant (derivative)50,000——Form 4
2026-05-20Mandel-Brehm Josh · directorAward / grant (derivative)5,500——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 25 reporting institutions held 6.1M shares ($78.0M, 68.5% of shares outstanding).

#InstitutionSharesValue
1JANUS HENDERSON GROUP PLC1,292,757$16.4M
2Deep Track Capital, LP835,655$10.6M
3WELLINGTON MANAGEMENT GROUP LLP696,378$8.8M
4Trails Edge Capital Partners, LP557,103$7.1M
5Ally Bridge Group (NY) LLC414,219$5.3M
6Woodline Partners LP395,295$5.0M
7GREAT POINT PARTNERS LLC371,402$4.7M
8Yu Fan329,760$4.2M
9SPHERA FUNDS MANAGEMENT LTD.325,591$4.1M
10Squadron Capital Management LLC324,977$4.1M
11ADAGE CAPITAL PARTNERS GP, L.L.C.139,275$1.8M
12ADAR1 Capital Management, LLC95,350$1.2M
13683 Capital Management, LLC92,850$1.2M
14MILLENNIUM MANAGEMENT LLC77,921$990K
15Empery Asset Management, LP60,353$766K